The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders / Frisoni, G. B.; Festari, C.; Massa, F.; Cotta Ramusino, M.; Orini, S.; Aarsland, D.; Agosta, F.; Babiloni, C.; Borroni, B.; Cappa, S. F.; Frederiksen, K. S.; Froelich, L.; Garibotto, V.; Haliassos, A.; Jessen, F.; Kamondi, A.; Kessels, R. P.; Morbelli, S. D.; O'Brien, J. T.; Otto, M.; Perret-Liaudet, A.; Pizzini, F. B.; Vandenbulcke, M.; Vanninen, R.; Verhey, F.; Vernooij, M. W.; Yousry, T.; Boada Rovira, M.; Dubois, B.; Georges, J.; Hansson, O.; Ritchie, C. W.; Scheltens, P.; van der Flier, W. M.; Nobili, F.. - In: LANCET NEUROLOGY. - ISSN 1474-4422. - 23:3(2024), pp. 302-312. [10.1016/S1474-4422(23)00447-7]

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Agosta F.;Cappa S. F.;
2024-01-01

Abstract

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1474442223004477-main.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 368.27 kB
Formato Adobe PDF
368.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/160779
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact